Clinical Trial Detail

NCT ID NCT03065400
Title PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors John Mascarenhas
Indications

myelofibrosis

essential thrombocythemia

bone marrow cancer

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.